Identification and Validation of <i>RELN</i> Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer

Identification and Validation of <i>RELN</i> Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer

Remarkable clinical benefits in several advanced cancers are observed under the treatment of immune checkpoint inhibitor (ICI) agents. However, only a smaller proportion of patients respond to the treatments. Reelin (RELN) is frequently mutated in the cancer genome. In this study, the <i>RELN&...

Full description

Bibliographic Details
Main Authors: Zhenpeng Li, Xin Wang, Yi Yang, Fuyan Shi, Wenjing Zhang, Qinghua Wang, Suzhen Wang
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Cells
Subjects:
<i>RELN</i> mutations
immune checkpoint inhibitor
melanoma
non-small cell lung cancer
molecular determinant
Online Access:https://www.mdpi.com/2073-4409/11/23/3841

Similar Items

Similar Items